GCP
BEAM icon

GSA Capital Partners’s Beam Therapeutics BEAM Stock Holding History

GSA Capital Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,785
Closed -$283K – 1509
2023
Q3 		$283K Buy
+11,785
New +$316K 0.02% 1112
2022
Q4 		– Sell
-9,217
Closed -$439K – 1471
2022
Q3 		$439K Buy
9,217
+2,510
+37% +$143K 0.06% 672
2022
Q2 		$260K Buy
+6,707
New +$267K 0.04% 915

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

GSA Capital Partners's BEAM Position: Q4 2023 in Review

GSA Capital Partners sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 11,785 shares — an estimated $283K sold.

GSA Capital Partners first reported a position in BEAM in Q2 2022 and held it in 3 quarters. The position peaked at $439K in Q3 2022. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • GSA Capital Partners reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • GSA Capital Partners sold 11,785 Beam Therapeutics shares in Q4 2023, an estimated $283K.
  • GSA Capital Partners first reported a position in Beam Therapeutics in Q2 2022 and held it in 3 quarters.
  • GSA Capital Partners's Beam Therapeutics position peaked at $439K in Q3 2022.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.